Table 1. Clinical features of women with low- and high-grade serous ovarian carcinomas.
| Clinical features | Low-grade serous ovarian carcinoma (LGSOC) | High-grade serous ovarian carcinoma (HGSOC) | |
|---|---|---|---|
| n (%) | n (%) | p value | |
| 21 (19.8) | 85 (80.2) | ||
| Age median (range), in years | 55 (26–78) | 59 (19–85) | 0.83 |
| Menopausal status | |||
| Pre-menopausal | 6 (28.6) | 20 (23.5) | |
| Post-menopausal | 15 (71.4) | 65 (76.5) | 0.78 |
| FIGO staging | |||
| I + II | 12 (57.1) | 17 (20.0) | |
| III + IV | 9 (42.9) | 68 (80.0) | <0.001 |
| CA125 median (1st; 3rd quartile) in U/ml | 98 (21; 378) | 954 (194; 2248) | <0.001 |
| Post-surgery residual disease | |||
| No | 17 (80.9) | 40 (47.0) | |
| Yes | 4 (19.1) | 45 (53.0) | <0.01 |
| Response to platinum-based chemotherapy* | |||
| Platinum-sensitive | 10 (91.0) | 41 (63.1) | |
| Platinum-refractory/resistant | 1 (9.0) | 24 (36.9) | 0.09 |
| Recurrence/disease progression | |||
| No | 16 (76.2) | 32 (37.7) | |
| Yes | 5 (23.8) | 53 (62.3) | 0.001 |
FIGO: The International Federation of Gynecology and Obstetrics; LGSOC: low-grade serous ovarian carcinoma; HGSOC: high-grade ovarian serous carcinoma; *6 LGSOC patients did not undergo chemotherapy because they were stage I FIGO and 8 HGSOC patients did not undergo chemotherapy because they died; LGSOC and HGSOC women with acquired resistance were not included in this analysis; statistically significant differences are in bold, p values were calculated using the Chi square/Fisher exact test or the Mann-Whitney test.